Tafamidis Solid-State Forms for Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of tafamidis lack desirable properties such as improved processing, handling characteristics, stability, and bioavailability, which are crucial for effective treatment of transthyretin-mediated amyloidosis.
Innovation Solution
Development of novel solid state forms and salts of tafamidis, including crystalline forms and amorphous forms, characterized by specific PXRD patterns and 13C NMR spectra, which offer enhanced properties like chemical stability, solubility, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If existing formulations of tafamidis are used, then the treatment can be administered, but the processing and handling characteristics are poor and stability is insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing multiple solid state forms (polymorphs) of tafamidis, each with different physical properties such as melting point, density, and solubility. By changing the physical state parameters of the drug substance, the formulation achieves improved processing characteristics while maintaining stability. Specific examples include Form I with high melting point and Form II with lower melting point, each suitable for different formulation requirements.
Solution Approach 2:
The patent creates composite materials by forming salts and solvates of tafamidis with various counterions and solvent molecules. These composite structures (e.g., tafamidis meglumine, tafamidis acetate solvate) combine the properties of different components to achieve both improved processing characteristics and stability. The composite approach allows optimization of both manufacturing ease and reliability through synergistic property combination.
2Productivity
If existing formulations of tafamidis are used, then the treatment can be administered, but the dissolution profile and bioavailability are insufficient
Solution Approach 1:
The patent utilizes parameter changes by selecting specific solid state forms with optimized physical properties that enhance dissolution and bioavailability. Different polymorphic forms have different lattice energies and surface areas, which directly affect dissolution rate. The patent identifies forms with appropriate melting points and solubility characteristics that improve bioavailability while ensuring reliable dissolution profiles for consistent therapeutic effect.
Solution Approach 2:
The patent applies phase transitions by utilizing the different physical states and phase change properties of various tafamidis polymorphs. The transition between different solid phases and the melting behavior of specific forms (e.g., Form I with high melting point vs. Form II with lower melting point) is exploited to control dissolution characteristics and improve bioavailability while maintaining reliable dissolution profiles.
3Adaptability or versatility
If multiple solid state forms are discovered, then the repertoire of materials is enlarged, but the complexity of characterization and selection increases
Solution Approach 1:
The patent applies segmentation by systematically categorizing and characterizing different solid state forms based on their specific properties such as melting point, density, and PXRD patterns. This segmentation allows the complex repertoire of materials to be organized into distinct groups (e.g., Form I, Form II, Form III with different characteristics), making the characterization and selection process more manageable despite the increased versatility.
Solution Approach 2:
The patent replaces complex manual characterization procedures with standardized analytical techniques and criteria. By establishing defined characterization methods (PXRD, DSC, TGA, NMR) and selection criteria, the complexity of evaluating multiple solid state forms is reduced. The systematic application of these standardized methods enables efficient navigation through the enlarged material repertoire without proportionally increasing operational complexity.
Data Source
AI summary
The present disclosure relates to solid state forms of Tafamidis and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.